siRNA function in RNAi: A chemical modification analysis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Various chemical modifications were created in short-interfering RNAs (siRNAs) to determine the biochemical properties required for RNA interference (RNAi). Remarkably, modifications at the 2′-position of pentose sugars in siRNAs showed the 2′-OHs were not required for RNAi, indicating that RNAi machinery does not require the 2′-OH for recognition of siRNAs and catalytic ribonuclease activity of RNA-induced silencing complexes (RISCs) does not involve the 2′-OH of guide antisense RNA. In addition, 2′ modifications predicted to stabilize siRNA increased the persistence of RNAi as compared with wild-type siRNAs. RNAi was also induced with chemical modifications that stabilized interactions between A–U base pairs, demonstrating that these types of modifications may enhance mRNA targeting efficiency in allele-specific RNAi. Modifications altering the structure of the A-form major groove of antisense siRNA–mRNA duplexes abolished RNAi, suggesting that the major groove of these duplexes was required for recognition by activated RISC*. Comparative analysis of the stability and RNAi activities of chemically modified single-stranded antisense RNA and duplex siRNA suggested that some catalytic mechanism(s) other than siRNA stability were linked to RNAi efficiency. Modified or mismatched ribonucleotides incorporated at internal positions in the 5′ or 3′ half of the siRNA duplex, as defined by the antisense strand, indicated that the integrity of the 5′ and not the 3′ half of the siRNA structure was important for RNAi, highlighting the asymmetric nature of siRNA recognition for initiation of unwinding. Collectively, this study defines the mechanisms of RNAi in human cells and provides new rules for designing effective and stable siRNAs for RNAi-mediated gene-silencing applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dignam, J. D., Lebovitz, R. M., & Roeder, R. G. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.5.1475 · Cited by 11,260
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 4,892
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
RNA interference is mediated by 21- and 22-nucleotide RNAs
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,310
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells
Hammond, S. M., Bernstein, E., Beach, D., & Hannon, G. J. (2000) · Nature · doi:10.1038/35005107 · Cited by 3,003
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,676
A microRNA in a Multiple-Turnover RNAi Enzyme Complex
Hutvágner, G., & Zamore, P. D. (2002) · Science · doi:10.1126/science.1073827 · Cited by 1,674
Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi
Martinez, J., Patkaniowska, A., Urlaub, H., Lührmann, R., & Tuschl, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00908-x · Cited by 1,459
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate
Elbashir, S. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6877 · Cited by 1,449
Gene silencing in mammals by small interfering RNAs
McManus, M. T., & Sharp, P. A. (2002) · Nature Reviews Genetics · doi:10.1038/nrg908 · Cited by 1,399
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Asymmetry in the Assembly of the RNAi Enzyme Complex
Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00759-1 · Cited by 2,922
Gold Nanoparticles for Biology and Medicine
Giljohann, D. A., Seferos, D. S., Daniel, W. L., Massich, M. D., Patel, P. C., & Mirkin, C. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200904359 · Cited by 2,356
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
Repression of protein synthesis by miRNAs: how many mechanisms?
Pillai, R. S., Bhattacharyya, S. N., & Filipowicz, W. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.12.007 · Cited by 1,108
Illuminating the silence: understanding the structure and function of small RNAs
Rana, T. M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2085 · Cited by 1,083
“Therefore, helical geometry has been postulated as the major determinant for RNA being a specific trigger of gene silencin”
BackgroundSelf-citationsiRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Strategies for silencing human disease using RNA interference
Kim, D. H., & Rossi, J. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2006 · Cited by 1,078
“The strategic placement of these modifications is crucial, as modifications on the 5′ end of the guide strand can adversely affect silencing potenc”
BackgroundMolecular Mechanisms of RNA Interference
Wilson, R. C., & Doudna, J. A. (2013) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-083012-130404 · Cited by 1,076
Unlocking the potential of the human genome with RNA interference
Hannon, G. J., & Rossi, J. J. (2004) · Nature · doi:10.1038/nature02870 · Cited by 1,064
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Self-citationRevealing the world of RNA interference
Mello, C. C., & Conte, D. (2004) · Nature · doi:10.1038/nature02872 · Cited by 997
Perspective: machines for RNAi
Tomari, Y., & Zamore, P. D. (2005) · Genes & Development · doi:10.1101/gad.1284105 · Cited by 948
siRNAs: applications in functional genomics and potential as therapeutics
Dorsett, Y., & Tuschl, T. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1345 · Cited by 909
RNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 789
Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain
Ma, J.-B., Ye, K., & Patel, D. J. (2004) · Nature · doi:10.1038/nature02519 · Cited by 732
The Crystal Structure of Human Argonaute2
Schirle, N. T., & MacRae, I. J. (2012) · Science · doi:10.1126/science.1221551 · Cited by 696
MicroRNA control of PHABULOSA in leaf development: importance of pairing to the microRNA 5′ region
Mallory, A. C., Reinhart, B. J., Jones‐Rhoades, M. W., Tang, G., Zamore, P. D., Barton, M. K., & Bartel, D. P. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600340 · Cited by 692
MicroRNA function: Multiple mechanisms for a tiny RNA?: FIGURE 1.
PILLAI, R. S. (2005) · RNA · doi:10.1261/rna.2248605 · Cited by 681
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
“A number of reports have described patterns of 2VO-methyl incorporation that retain full potency of the siRNA compared with unmodified RNA and are stable in serum [49,55,57].”
Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi protein
Ma, J.-B., Yuan, Y.-R., Meister, G., Pei, Y., Tuschl, T., & Patel, D. J. (2005) · Nature · doi:10.1038/nature03514 · Cited by 657
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
siRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
MicroRNA-Based Diagnosis and Therapy
Ho, P. T. B., Clark, I. M., & Le, L. T. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137167 · Cited by 630
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
“F) modification helps to protect against exonucleases, hence making the guide strand more stable, while it does not interfere with RISC loading (Chiu & Rana, 2003).”
Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 592
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
In vivo activity of nuclease-resistant siRNAs
LAYZER, J. M., MCCAFFREY, A. P., TANNER, A. K., HUANG, Z., KAY, M. A., & SULLENGER, B. A. (2004) · RNA · doi:10.1261/rna.5239604 · Cited by 580
Strategies, design, and chemistry in siRNA delivery systems
Dong, Y., Siegwart, D. J., & Anderson, D. G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.004 · Cited by 572
Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
Kinetic analysis of the RNAi enzyme complex
Haley, B., & Zamore, P. D. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb780 · Cited by 544
Application of gold nanoparticles in biomedical and drug delivery
Daraee, H., Eatemadi, A., Abbasi, E., Fekri Aval, S., Kouhi, M., & Akbarzadeh, A. (2016) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.3109/21691401.2014.955107 · Cited by 541
Translation Repression in Human Cells by MicroRNA-Induced Gene Silencing Requires RCK/p54
Chu, C.-Y., & Rana, T. M. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040210 · Cited by 520
Self-citationStructure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499
The growth of siRNA-based therapeutics: updated clinical studies
Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497
Monolayer coated gold nanoparticles for delivery applications
Rana, S., Bajaj, A., Mout, R., & Rotello, V. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.08.006 · Cited by 479
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Approaches for the sequence-specific knockdown of mRNA
Scherer, L. J., & Rossi, J. J. (2003) · Nature Biotechnology · doi:10.1038/nbt915 · Cited by 455
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Robbins, M., Judge, A., & MacLachlan, I. (2009) · Oligonucleotides · doi:10.1089/oli.2009.0180 · Cited by 449
siRNA and miRNA: an insight into RISCs
Tang, G. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.12.007 · Cited by 449
Allerson, C. R., Sioufi, N., Jarres, R., Prakash, T. P., Naik, N., Berdeja, A., Wanders, L., Griffey, R. H., Swayze, E. E., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049167j · Cited by 448
siRNA: Mechanism of action, challenges, and therapeutic approaches
Alshaer, W., Zureigat, H., Al Karaki, A., Al-Kadash, A., Gharaibeh, L., Hatmal, M. M., Aljabali, A. A. A., & Awidi, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174178 · Cited by 441
Chemically modified siRNA: tools and applications
Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431
Principles and effects of microRNA-mediated post-transcriptional gene regulation
Engels, B. M., & Hutvagner, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209909 · Cited by 409
RISC is a 5′ phosphomonoester-producing RNA endonuclease
Martinez, J., & Tuschl, T. (2004) · Genes & Development · doi:10.1101/gad.1187904 · Cited by 407
Yuan, Y.-R., Pei, Y., Ma, J.-B., Kuryavyi, V., Zhadina, M., Meister, G., Chen, H.-Y., Dauter, Z., Tuschl, T., & Patel, D. J. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.07.011 · Cited by 396
Visualizing a Correlation between siRNA Localization, Cellular Uptake, and RNAi in Living Cells
Chiu, Y.-L., Ali, A., Chu, C.-Y., Cao, H., & Rana, T. M. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.06.006 · Cited by 381
Self-citationBramsen, J. B., Laursen, M. B., Nielsen, A. F., Hansen, T. B., Bus, C., Langkjær, N., Babu, B. R., Højland, T., Abramov, M., Van Aerschot, A., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp106 · Cited by 369
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V, Fisch, G., Dames, S., Löffler, K., Fechtner, M., Arnold, W., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302777 · Cited by 368
Activation of the mammalian immune system by siRNAs
Marques, J. T., & Williams, B. R. G. (2005) · Nature Biotechnology · doi:10.1038/nbt1161 · Cited by 358
Structure of yeast Argonaute with guide RNA
Nakanishi, K., Weinberg, D. E., Bartel, D. P., & Patel, D. J. (2012) · Nature · doi:10.1038/nature11211 · Cited by 356
Crystal structure of a PIWI protein suggests mechanisms for siRNA recognition and slicer activity
Parker, J. S., Roe, S. M., & Barford, D. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600488 · Cited by 350
Chemical modification of siRNAs to improve serum stability without loss of efficacy
Choung, S., Kim, Y. J., Kim, S., Park, H.-O., & Choi, Y.-C. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.049 · Cited by 348
RNA interference and chemically modified small interfering RNAs
Manoharan, M. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.10.007 · Cited by 346
siRNA Conjugate Delivery Systems
Jeong, J. H., Mok, H., Oh, Y.-K., & Park, T. G. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800278e · Cited by 338
The Silent Revolution: RNA Interference as Basic Biology, Research Tool, and Therapeutic
Dykxhoorn, D. M., & Lieberman, J. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104606 · Cited by 336
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
RNA Interference: From Basic Research to Therapeutic Applications
Kurreck, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802092 · Cited by 335
Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriers
Scholz, C., & Wagner, E. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.014 · Cited by 333
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
Foster, D. J., Brown, C. R., Shaikh, S., Trapp, C., Schlegel, M. K., Qian, K., Sehgal, A., Rajeev, K. G., Jadhav, V., Manoharan, M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.021 · Cited by 325
The silent treatment: siRNAs as small molecule drugs
Dykxhoorn, D. M., Palliser, D., & Lieberman, J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302703 · Cited by 324
Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol
Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H., & Yokota, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.14 · Cited by 312
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
siRNA therapeutics: big potential from small RNAs
Ryther, R. C. C., Flynt, A. S., Phillips, J. A., & Patton, J. G. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302356 · Cited by 301
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†
Morrissey, D. V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J. A., Dickinson, B., McSwiggen, J. A., Vargeese, C., Bowman, K., Shaffer, C. S., et al. (2005) · Hepatology · doi:10.1002/hep.20702 · Cited by 290
New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles
Zaimy, M. A., Saffarzadeh, N., Mohammadi, A., Pourghadamyari, H., Izadi, P., Sarli, A., Moghaddam, L. K., Paschepari, S. R., Azizi, H., Torkamandi, S., et al. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.16 · Cited by 289
Improving the efficiency of RNA interference in mammals
Mittal, V. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1323 · Cited by 286
Positional Effect of Chemical Modifications on Short Interference RNA Activity in Mammalian Cells
Prakash, T. P., Allerson, C. R., Dande, P., Vickers, T. A., Sioufi, N., Jarres, R., Baker, B. F., Swayze, E. E., Griffey, R. H., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050044o · Cited by 285
Chemical modification: the key to clinical application of RNA interference?
Corey, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33483 · Cited by 285
RNA interference using boranophosphate siRNAs: structure-activity relationships
Hall, A. H. S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh936 · Cited by 285
Overcoming the Innate Immune Response to Small Interfering RNA
Judge, A., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 284
Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Kanasty, R. L., Whitehead, K. A., Vegas, A. J., & Anderson, D. G. (2012) · Molecular Therapy · doi:10.1038/mt.2011.294 · Cited by 279
The RNA-Induced Silencing Complex Is a Mg2+-Dependent Endonuclease
Schwarz, D. S., Tomari, Y., & Zamore, P. D. (2004) · Current Biology · doi:10.1016/j.cub.2004.03.008 · Cited by 267
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 258
Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury
Hamar, P., Song, E., Kökény, G., Chen, A., Ouyang, N., & Lieberman, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406421101 · Cited by 250
The landscape of nanoparticle-based siRNA delivery and therapeutic development
Moazzam, M., Zhang, M., Hussain, A., Yu, X., Huang, J., & Huang, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.005 · Cited by 230
MicroRNA-based therapeutics in central nervous system injuries
Sun, P., Liu, D. Z., Jickling, G. C., Sharp, F. R., & Yin, K.-J. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18773871 · Cited by 228
Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., Memari, F., Miri, S. R., Rezvani Rad, M., & Marmari, V. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200253 · Cited by 221
Innate sensing of self and non-self RNAs by Toll-like receptors
Sioud, M. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.02.004 · Cited by 179
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
“F modification at most positions (Braasch et al., 2003; Chiu and Rana, 2003; Harborth et al., 2003; Prakash et al., 2005; Choung et al., 2006; Manoharan et al., 2011) and substitution of all siRNA pyrimidines was reported to greatly enhance serum stability and to support effective silencing in…”
BackgroundInfluentialNanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Mirón-Barroso, S., Domènech, E. B., & Trigueros, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168537 · Cited by 91
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Salemi, M., Mogavero, M. P., Lanza, G., Mongioì, L. M., Calogero, A. E., & Ferri, R. (2022) · Cells · doi:10.3390/cells11121930 · Cited by 39
Shin, S., Kim, Y. S., Kim, J., Kwon, H.-M., Kim, D.-E., & Hah, S. S. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0396 · Cited by 9
Metadata
- Authors
- CHIU, Y.-L., & RANA, T. M.
- Venue
- RNA
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-08-15
- Volume
- 9
- Issue
- 9
- Pages
- 1034-1048
- ISSN
- 1355-8382 (ISSN-L)
- 1469-9001
- OpenAlex
- W2121133384
- Cited by
- 860
- References
- 34
- FWCI
- 15.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.